Lidogrell is a dual-acting agent that can be used to prevent systemic thromboembolism and as an adjunct to thrombolytic therapy in acutemyocardialinfarction.
MitoA is a ratiometric mass spectrometry probe that can be used for assessing changes in H2S within mitochondria in vivo. MitoA contains a triphenylphosphonium cation component that drives its accumulation in mitochondria where its aryl azide moiety selectively reacts with H2S to produce an amine product, MitoN. Quantifying the MitoN MitoA ratio by LC-MS MS reflects the mitochondrial matrix H2S concentration. In a mouse model of acutemyocardialinfarction with MitoA administered prior to ischemia, the MitoN MitoA ratio is increased only in the region of ischemia.
MMPI-1154 is a highly promising imidazole-carboxylic acid (ICA) MMP-2 inhibitor (IC 50 = 6.6 μM) with excellent cardio-cytoprotective properties. It is specifically designed for the study of acutemyocardialinfarction. Additionally, MMPI-1154 exhibits significant inhibitory effects on MMP-13, MMP-1, and MMP-9 activities with IC 50 values of 1.8 μM, 10 μM, and 13 μM, respectively.
Aralosides possess protective effect against experimental myocardial ischemia and infarction, the mechanism of myocardial protection may be attributed to the amelioration of FFA metabolic deterioration and membrane peroxidation induced by oxygen free radi
Tiapamil Free Base is a phenylethylamine derivative that acts as a calcium antagonist showing hemodynamic effects in patients with acutemyocardialinfarction.